about
Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.Impact of acetylsalicylic Acid on the clinicopathological characteristics and prognosis of patients with invasive breast cancer.Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.Peripheral T-cell lymphoma and Job's syndrome: a rare association.Targeted therapies in gastric cancer and future perspectives.Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma.Clinicopathologic features of gastric cancer in young patients.Pertuzumab in HER2-positive breast cancer.Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.Cardiotoxicity of novel HER2-targeted therapies.Everolimus: a new hope for patients with breast cancer.Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma.A comprehensive review of denosumab for bone metastasis in patients with solid tumors.Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkn's lymphoma patient.Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale".Breast cancer subtypes and outcomes of central nervous system metastases.Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer.Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin.Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy.The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration.Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia.The Effect of Total Size of Lesions in Multifocal/Multicentric Breast Cancer on Survival.Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience.Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.Long-term survivors among breast cancer patients with brain metastases.Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer.Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response.Other malignancies in patients with breast cancer: a single institute experience.Duodenal adenocarcinoma: A rare cause of chyloperitoneum (chylous ascites).Metastatic granular cell tumor: a case report and review of the literature.Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia.Clinical and pathological characteristics of breast cancer patients with history of cesarean deliverySuccessful treatment of chronic hiccup with baclofen in cancer patients.Hypertrichosis after surgery for cubital tunnel syndrome
P50
Q33436548-1B06EAB2-FCE1-4664-ABBC-F2850D2E7309Q33735212-D4309C92-8E17-432D-A714-B0F1C18F3177Q34403601-706CE149-1236-428C-ABC5-58AF6E6DFBFEQ36419177-6C6D4728-EC78-41DF-88F4-B14646AC899BQ36462765-9835BED0-3760-4D7C-ABFB-E7AEDE3B7698Q36471685-069E2A18-1D37-4598-9123-A8E6107E55B9Q37551463-FEB39CFA-FBC4-4777-AF13-76EEEF32FAB0Q37645714-39A5B8D7-3E54-404F-80B0-E8D245E5C3FBQ38041194-E93E6B63-6021-4225-B18E-EF549F80EB43Q38080898-B8E46612-6472-4222-8C61-B497517FFD85Q38108380-57BB7079-B382-4A84-95ED-1672FB09E689Q38139585-C89692CA-576D-42C7-8086-AF4CF4EACEAFQ38195907-F5A379B7-806A-4567-A603-86C0546BC949Q38602989-4B51555A-4E08-429D-A17D-B199B3CF8D24Q39062391-020332CF-AEC0-42B0-8549-6B6CD273896BQ41753656-AADECB56-FE52-40AE-9D3D-33086D0A898EQ42438761-EEE7D37B-F864-43A6-85E1-2491C3581AE6Q42725985-6C928663-B890-4A05-9A7B-AD5AB4EB4645Q43466291-4D2C7804-C0AB-4387-BBBE-FE0305767C14Q43781103-AB5EBDB2-F81A-4237-8C53-A516131CABEEQ43966702-E6F4AAE1-0A05-4403-B7C5-B0F8BFC8E8C1Q44125298-D8082CFF-107A-428E-9FC3-468A19340764Q44459340-88A7A0B6-8411-4551-B1C9-6921961BA695Q44793423-9F78217E-55A7-47C3-9AE6-688EF26EB1A0Q44823995-D0EDB7F0-0DED-4A52-A225-35E5755C3FD0Q46235486-D6BADF27-170A-4210-8303-0E71BD231D2FQ47175343-E1F6BF07-25DE-46F1-B664-3710E82CFE09Q47201830-713B253A-3E0C-48A7-8FA6-2F61EC3FF663Q48377429-E3CA31C4-8EAD-44F7-B898-9913D35F07EFQ48393324-8B5A52AB-9430-405B-AB60-7C8A8E7B2907Q48535434-A0295FE3-A461-41A1-934F-DCD06A6B86E2Q48567182-144218C8-297D-4159-86DD-679949A30748Q50517387-97509E56-551F-4DAC-95B0-732BDAD334E9Q51798126-5BF7E97E-4B9F-40B6-8CCD-5452DBE791F9Q53186680-EA430DFD-AEA4-4C14-BF52-B88F28175948Q53552716-C108CFB0-EAB8-47AA-8C0A-D1000419BF07Q53759587-EE736005-77EC-45CF-8DFB-395EB3997DD0Q61841156-5D56EF0A-139E-4328-A651-D5B83DECB3D0Q64945760-443E0F8A-9165-44BD-A528-EE30547FF571Q83219154-25421737-7FE3-4FD5-AC93-A0423DD125C8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sercan Aksoy
@ast
Sercan Aksoy
@en
Sercan Aksoy
@es
Sercan Aksoy
@nl
type
label
Sercan Aksoy
@ast
Sercan Aksoy
@en
Sercan Aksoy
@es
Sercan Aksoy
@nl
prefLabel
Sercan Aksoy
@ast
Sercan Aksoy
@en
Sercan Aksoy
@es
Sercan Aksoy
@nl
P106
P1153
7006512389
P31
P496
0000-0003-4984-1049